Role of neuroimaging in drug development

Reviews in the Neurosciences

Volumn 25, Issue 5, 2014, Pages 663-673

  Medhi, Bikash ^a   Misra, Shubham ^a   Avti, Pramod Kumar ^b   Kumar, Pardeep ^a   Kumar, Harish ^a   Singh, Baljinder ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

CT; drug development; MRI; MRS; neuroimaging; PET; SPECT

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONITRILE F 18; AZD 2184 C 11; CANNABINOID 1 RECEPTOR AGONIST; CARBON 11; CHELATING AGENT; CIPROFLOXACIN TC 99M; CYCLOPHOSPHAMIDE; DOXORUBICIN; DYSPROSIUM; FLORBETABEN; FLORBETAPIR F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; GADOLINIUM; INDIUM 111; IODINE; IRON OXIDE; MK 0233 C 11; MK 9470 F 18; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NEW DRUG; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXYGEN 15; PACLITAXEL; PITTSBURGH COMPOUND B; SB 13 C 11; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL IMAGING SYSTEM; ARTICLE; BIOLUMINESCENCE; BIOLUMINESCENCE IMAGING; BRAIN TOMOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ELECTRON SPIN RESONANCE; FLUORESCENCE MEDIATED MOLECULAR TOMOGRAPHY; FLUORESCENCE REFLECTANCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE RECONSTRUCTION; ISOTOPE LABELING; MICROBUBBLE; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; NEAR INFRARED SPECTROSCOPY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; RADIOACTIVITY; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; X RAY DETECTOR; ANIMAL; DRUG DEVELOPMENT; MULTIMODAL IMAGING; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; NEUROIMAGING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84908158765     PISSN: 03341763     EISSN: 21910200     Source Type: Journal    
DOI: 10.1515/revneuro-2014-0031     Document Type: Article

References (56)

1. Acton, P.D., Hou, C., Kung, M.P., Plossl, K., Keeney, C.L., and Kung, H.F. (2002). Occupancy of dopamine D 2 receptors in the mouse brain measured using ultra-high-resolution singlephoton emission tomography and [123 I] IBF. Eur. J. Nucl. Med. Mol. Imaging. 29, 1507-1515.
2. Agdeppa, E.D., Kepe, V., Liu, J., Small, G.W., Huang, S.C., Petric, A., Satyamurthy, N., and Barrio, J.R. (2003). 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol. Imaging Biol. 5, 404-417.
3. Bailey, D.L., Townsend, D.W., Valk, P.E., and Maisey, M.N. (2004). Positron Emission Tomography: Basic Sciences. 1st edn. (New York, US: Springer). ISBN: 978-1-84628-007-8.
4. Banati, R.B. (2002). Visualising microglial activation in vivo. Glia. 40, 206-217.
5. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., and Johnson-Wood, K. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916-919.
6. Benveniste, H., Einstein, G., Kim, K.R., Hulette, C., and Johnson, G.A. (1999). Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc. Natl. Acad. Sci. USA 96, 14079-14084.
7. Blankenberg, F.G. and Strauss, H.W. (2002). Nuclear medicine applications in molecular imaging. J. Nucl. Med. Mol. Imaging 16, 352-361.
8. Borthakur, A., Gur, T., Wheaton, A.J., Corbo, M., Trojanowski, J.Q., Lee, V.M.Y., and Reddy, R. (2006). In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J. Magn. Reson. Imaging 24, 1011-1017.
9. Braakman, N., Matysik, J., van Duinen, S.G., Verbeek, F., Schliebs, R., de Groot, H.J.M., and Alia, A. (2006). Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 24, 530-536.
10. Brunner, M. and Langer, O. (2006). Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J. 8, 263-271.
11. Burns, H.D., Van Laere, K., Sanabria-Bohórquez, S., Hamill, T.G., Bormans, G., Eng, W., Gibson, R., Ryan, C., Connolly, B., Patel, S., et al. (2007). [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Natl. Acad. Sci. USA 104, 9800-9805.
12. Cagnin, A., Brooks, D.J., Kennedy, A.M., Gunn, R.N., Myers, R., Turkheimer, F.E., Jones, T., and Banati, R.B. (2001). In-vivo measurement of activated microglia in dementia. Lancet. 358, 461-467.
13. Chamberlain, R., Wengenack, T.M., Poduslo, J.F., Garwood, M., and Jack Jr, C.R. (2011). Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr. Med. Imaging Rev. 7, 3-7.
14. Colby, L.A. and Morenko, B.J. (2004). Clinical considerations in rodent bioimaging. Comp. Med. 54, 623-630.
15. Dhenain, M., El Tannir El Tayara, N., Wu, T.D., Guegan, M., Volk, A., Quintana, C., and Delatour, B. (2009). Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol. Aging. 30, 41-53.
16. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. (2003). The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-186.
17. Eckelman, W.C., Reba, R.C., Gibson, R.E., Rzeszotarski, W.J., Vieras, F., Mazaitis, J.K., and Francis, B. (1979). Receptor-binding radiotracers: a class of potential radiopharmaceuticals. J. Nucl. Med. 20, 350-357.
18. Erondu, N., Gantz, I., Musser, B., Suryawanshi, S., Mallick, M., Addy, C., Cote, J., Bray, G., Fujioka, K., and Bays, H. (2006). Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 4, 275-282.
19. Gerdelat-Mas, A., Loubinoux, I., Tombari, D., Rascol, O., Chollet, F., and Simonetta-Moreau, M. (2005). Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage. 27, 314-322.
20. Goekoop, R., Rombouts, S.A.R.B., Jonker, C., Hibbel, A., Knol, D.L., Truyen, L., Barkhof, F., and Scheltens, P. (2004). Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. Neuroimage. 23, 1450-1459.
21. Haacke, E.M., Brown, R.W., Thompson, M.R., and Venkatesan, R. (1999). Magnetic Resonance Imaging: Physical Principles and Sequence Design (New York: A John Wiley and Sons).
22. Hargreaves, R. (2008). The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 83, 349-353.
23. Honey, G. and Bullmore, E. (2004). Human pharmacological MRI. Trends Pharmacol. Sci. 25, 366-374.
24. Hume, S.P., Gunn, R.N., and Jones, T. (1998). Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur. J. Nucl. Med. 25, 173-176.
25. Jack, C.R., Garwood, M., Wengenack, T.M., Borowski, B., Curran, G.L., Lin, J., Adriany, G., Grahmn, O.H.J., Grimm, R., and Poduslo, J.F. (2004). In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 52, 1263-1271.
26. Kalen, J.D., Hirsch, J.I., Kurdziel, K.A., Eckelman, W.C., and Kiesewetter, D.O. (2007). Automated synthesis of 18F analogue of paclitaxel (PAC): [18F] Paclitaxel (FPAC). Appl. Radiat. Isot. 65, 696-700.
27. Keller, M.D., Galloway, G.J., and Pollitt, C.C. (2006). Magnetic resonance microscopy of the equine hoof wall: a study of resolution and potential. Equine. Vet. J. 38, 461-466.
28. Kumar, P., Singh, B., Sharma, S., Ghai, A., Chuttani, K., Mishra, A.K., Dhawan, D.K., and Mittal, B.R. (2012). Pre-clinical evaluation of [99m]Tc labeled doxorubicin as a potential scintigraphic probe for tumor imaging. Cancer Biother. Radiopharmaceut. 27, 221-225.
29. Kuntner, C., Kesner, A.L., Bauer, M., Kremslehner, R., Wanek, T., Mandler, M., Karch, R., Stanek, J., Wolf, T., and Müller, M., (2009). Limitations of small animal PET imaging with [18 F] FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 11, 236-240.
30. Lacan, G., Kesner, A.L., Gangloff, A., Zheng, L., Czernin, J., Melega, W.P., and Silverman, D.H.S. (2005). Synthesis of 2-[(2-chloro-2′-[18F]fluoroethyl)amino]-2H-1,3,2-oxazaphosphorinane-2-oxide (18F-fluorocyclophosphamide) a potential tracer for breast tumor prognostic imaging with PET. J. Label. Comp. Radiopharm. 48, 635-643.
31. Langer, O. and Muller, M. (2004). Methods to assess tissue-specific distribution and metabolism of drugs. Curr. Drug Metab. 5, 463-481.
32. Logan, J. (2003). A review of graphical methods for tracer studies and strategies to reduce bias. Nucl. Med. Biol. 30, 833-844.
33. McGeer, P.L., Itagaki, S., Boyes, B.E., and McGeer, E.G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38, 1285-1285.
34. Meikle, S.R., Kench, P., Kassiou, M., and Banati, R.B. (2005). Small animal SPECT and its place in the matrix of molecular imaging technologies. Phys. Med. Biol. 50, R45.
35. Muller, U., Suckling, J., Zelaya, F., Honey, G., Faessel, H., Williams, S.C.R., Routledge, C., Brown, J., Robbins, T.W., and Bullmore, E.T. (2005). Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacol. 180, 624-633.
36. Murgo, A.J., Kummar, S., Rubinstein, L., Gutierrez, M., Collins, J., Kinders, R., Parchment, R.E., Ji, J., Steinberg, S.M., and Yang, S.X. (2008). Designing phase 0 cancer clinical trials. Clin. Cancer Res. 14, 3675-3682.
37. Nichol, C. and Kim, E.E. (2001). Molecular imaging and gene therapy. J. Nucl. Med. 42, 1368-1374.
38. Olsen, A.K., Keiding, S., and Munk, O.L. (2006). Effect of hypercapnia on cerebral blood flow and blood volume in pigs studied by positron emission tomography. Comp. Med. 56, 416-420.
39. Phelps, M.E. (2000). PET: the merging of biology and imaging into molecular imaging. J. Nucl. Med. 41, 661-681.
40. Prokop, M., Galanski, M., van der Molen, A., and Schaefer-Prokop, C. (2003). Spiral and multislice computed tomography of the body. 1st edition, New York, USA: Thieme. ISBN: 9783131164810.
41. Reiman, E.M. and Langbaum, J.B.S. (2009). Brain Imaging in the Evaluation of Putative Alzheimer's Disease Slowing. Risk-Reducing and Prevention Therapies (Oxford, UK: Oxford University Press), pp. 319-350.
42. Reiman, E.M., Langbaum, J.B.S., and Tariot, P.N. (2010). Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers 4, 3-14.
43. Singh, B., Sunil, H.V., Sharma, S., Prasad, V., Kashyap, R., Bhattacharya, A., Mittal, B.R., Taneja, A., Rai, R., Goni, V.G., et al. (2008). Efficacy of indigenously developed single vial kit preparation of 99mTc-ciprofloxacin in the detection of bacterial infection: an Indian experience. Nucl. Med. Commun. 29, 1123-1129.
44. Stein, E.A., Pankiewicz, J., Harsch, H.H., Cho, J.K., Fuller, S.A., Hoffmann, R.G., Hawkins, M., Rao, S.M., Bandettini, P.A., and Bloom, A.S. (1998). Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am. J. Psychiatry 155, 1009-1015.
45. Talbot, P.S., and Laruelle, M. (2002). The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol. 12, 503-511.
46. Tan, J., Town, T., and Mullan, M. (2002). CD40-CD40L interaction in Alzheimer's disease. Curr. Opin. Pharmacol. 2, 445-451.
47. Tempany, C.M. and McNeil, B.J. (2001). Advances in biomedical imaging. J. Am. Med. Assoc. 285, 562-567.
48. Teng, E., Kepe, V., Frautschy, S.A., Liu, J., Satyamurthy, N., Yang, F., Chen, P.P., Cole, G.B., Jones, M.R., Huang, S.C., et al. (2011). [F-18]FDDNP microPET imaging correlates with brain A burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-A antibody treatment. Neurobiol. Dis. 43, 565-575.
49. Toyama, H., Ye, D., Ichise, M., Liow, J.S., Cai, L., Jacobowitz, D., Musachio, J.L., Hong, J., Crescenzo, M., Tipre, D., et al. (2005). PET imaging of brain with the beta-amyloid probe,[11 C] 6-OHBTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 32, 593-600.
50. Turner, D.C., Robbins, T.W., Clark, L., Aron, A.R., Dowson, J., and Sahakian, B.J. (2003). Relative lack of cognitive effects of methylphenidate in elderly male volunteers. Psychopharmacology 168, 455-464.
51. Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., and Van der Linden, A. (2005). Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP [V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 53, 607-613.
52. Venneti, S., Lopresti, B.J., Wang, G., Hamilton, R.L., Mathis, C.A., Klunk, W.E., Apte, U.M., and Wiley, C.A. (2009). PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging. 30, 1217-1226.
53. Vollm, B.A., de Araujo, I.E., Cowen, P.J., Rolls, E.T., Kringelbach, M.L., Smith, K.A., Jezzard, P., Heal, R.J., and Matthews, P.M. (2004). Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacol. 29, 1715-1722.
54. Wilcock, D.M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D., Wilson, N., Freeman, M.J., and Gordon, M.N. (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 24, 6144-6151.
55. Yang, D., Xie, Z., Stephenson, D., Morton, D., Hicks, C.D., Brown, T.M., Sriram, R., O'Neill, S., Raunig, D., and Bocan, T. (2011). Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage. 54, 2652-2658.
56. Zhang, J., Yarowsky, P., Gordon, M.N., Di Carlo, G., Munireddy, S., van Zijl, P., and Mori, S. (2004). Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn. Reson. Med. 51, 452-457.